cellceutix, Inc. (CTIX)

Oncology Corporate Profile

Stock Performance

1.8000
-0.0200

HQ Location

100 Cumming Center, Suite 151-B
Beverly, MA 1915

Company Description

cellceutix is a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology and antimicrobial applications. Cellceutix believes it has a world-class portfolio of compounds and is now engaged in advancing its compounds and seeking strategic partnerships. Cellceutix's anti-cancer drug Kevetrin is currently in a Phase 1 clinical trial at Harvard Cancer Centers' Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center. In the laboratory Kevetrin has shown to induce activation of p53, often referred to as the "Guardian Angel Gene" due to its crucial role in controlling cell mutations.

Website: http://cellceutix.com/

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
kevetrinimmunotherapyOvarian cancerI

View additional information on product candidates here »

Pipeline image

Source


http://cellceutix.com/

Recent News Headlines

Cellceutix Reports Very Encouraging Interim Analysis of Phase 2 Drug Candidate Brilacidin for Severe Oral Mucositis (OM) in Head and Neck Cancer Patients; High Potential for Preventative Treatment

3/27/2017 02:00 pm

[GlobeNewswire] - BEVERLY, Mass., March 27, 2017-- Cellceutix Corporation,, today presented positive results from the Company's ongoing randomized, double-blind Phase 2 study of Brilacidin in the prevention and control ...

Cellceutix Releases Favorable Topline Findings as Part of Interim Analysis of Phase 2 Drug Candidate Brilacidin for the Treatment of Inflammatory Bowel Disease

3/21/2017 11:03 am

[GlobeNewswire] - BEVERLY, Mass., March 21, 2017-- Cellceutix Corporation,, a clinical stage biopharmaceutical company developing innovative therapies with dermatology, oncology, anti-inflammatory, and antibiotic applications, ...

Cellceutix’s Phase 2 Drug Candidate Brilacidin Emerging as a Potential Novel Non-Biologic Therapy in Treating Inflammatory Bowel Disease

3/16/2017 11:03 am

[GlobeNewswire] - BEVERLY, Mass., March 16, 2017-- Cellceutix Corporation,, a clinical stage biopharmaceutical company developing innovative therapies with dermatology, oncology, anti-inflammatory, and antibiotic applications, ...

Cellceutix Releases Preliminary Efficacy and Safety Data in Interim Analysis of First Two Cohorts in Phase 2 Trial of Brilacidin for the Induction of Remission of Mild-to-Moderate Ulcerative Colitis

3/8/2017 12:03 pm

[GlobeNewswire] - BEVERLY, Mass., March 08, 2017-- Cellceutix Corporation,, a clinical stage biopharmaceutical company developing innovative therapies with dermatology, oncology, anti-inflammatory, and antibiotic applications, ...

Cellceutix Provides Update on Developing p53 Drug Candidate Kevetrin as an Oral Anti-Cancer Agent

3/3/2017 08:05 pm

[GlobeNewswire] - BEVERLY, Mass., March 03, 2017-- Cellceutix Corporation,, a clinical stage biopharmaceutical company developing innovative therapies with dermatology, oncology, anti-inflammatory, and antibiotic applications, ...

Cellceutix Phase 2 Brilacidin Trial Progresses to Highest Dose Cohort for the Induction of Remission of Mild-to-Moderate Ulcerative Colitis

2/22/2017 05:04 pm

[GlobeNewswire] - BEVERLY, Mass., Feb. 22, 2017-- Cellceutix Corporation,, a clinical stage biopharmaceutical company developing innovative therapies with dermatology, oncology, anti-inflammatory, and antibiotic applications, ...

Cellceutix Reports on Q2 Fiscal 2017, Prepares for Important Clinical Milestones

2/16/2017 12:03 pm

[GlobeNewswire] - BEVERLY, Mass., Feb. 16, 2017-- Cellceutix Corporation,, a clinical stage biopharmaceutical company developing innovative therapies with dermatology, oncology, anti-inflammatory, and antibiotic applications, ...

CELLCEUTIX CORP Financials

2/15/2017 06:00 pm

Cellceutix Announces Initiation of Main Clinical Site for Phase 2a Trial of p53 Drug Candidate Kevetrin in the Treatment of Platinum-Resistant/Refractory Ovarian Cancer

2/10/2017 01:00 pm

[GlobeNewswire] - BEVERLY, Mass., Feb. 10, 2017-- Cellceutix Corporation,, a clinical stage biopharmaceutical company developing innovative therapies with dermatology, oncology, anti-inflammatory, and antibiotic applications, ...

Cellceutix’s Brilacidin Demonstrates Promise in Treating Ulcerative Colitis Supported by Endoscopic Assessment, Patient-Reported Outcomes

1/23/2017 12:00 pm

[GlobeNewswire] - BEVERLY, Mass., Jan. 23, 2017-- Cellceutix Corporation,, a clinical stage biopharmaceutical company developing innovative therapies with dermatology, oncology, anti-inflammatory, and antibiotic applications, ...

Cellceutix Strongly Denounces Criminal Enterprise Mako Research, Who Published “Fake News” Full of Lies and Innuendo

1/17/2017 07:04 pm

[GlobeNewswire] - BEVERLY, Mass., Jan. 17, 2017-- Cellceutix Corporation,, a clinical stage biopharmaceutical company developing innovative therapies with dermatology, oncology, anti-inflammatory, and antibiotic applications, ...

Cellceutix Completes Enrollment in Second of Three Planned Cohorts in Phase 2 Clinical Trial of Brilacidin for Inflammatory Bowel Disease

1/17/2017 03:00 pm

[GlobeNewswire] - BEVERLY, Mass., Jan. 17, 2017-- Cellceutix Corporation,, a clinical stage biopharmaceutical company developing innovative therapies with dermatology, oncology, anti-inflammatory, and antibiotic applications, ...

Cellceutix to Present at Biotech Showcase 2017; Brilacidin for Oral Mucositis Nears Interim Results

1/4/2017 01:01 pm

[GlobeNewswire] - BEVERLY, Mass., Jan. 04, 2017-- Cellceutix Corporation,, a clinical stage biopharmaceutical company developing innovative therapies with dermatology, oncology, anti-inflammatory, and antibiotic applications, ...

Cellceutix Wishes Shareholders Happy Holidays, Prepares for 2017 Focused on Partnerships

12/22/2016 03:00 pm

[GlobeNewswire] - BEVERLY, Mass., Dec. 22, 2016-- Cellceutix Corporation,, a clinical stage biopharmaceutical company developing innovative therapies with dermatology, oncology, anti-inflammatory, and antibiotic applications, ...

Cellceutix Reports 24 Core Phase 2b Clinical Trial Sites for Oral Prurisol Treatment of Moderate-To-Severe Psoriasis Initiated and Open for Screening

12/19/2016 12:03 pm

[GlobeNewswire] - BEVERLY, Mass., Dec. 19, 2016-- Cellceutix Corporation, a clinical stage biopharmaceutical company developing innovative therapies with dermatology, oncology, anti-inflammatory, and antibiotic applications, ...

Cellceutix Reports Advances in Developing Kevetrin as an Oral Ovarian Cancer Treatment; Company Seeks to Develop World’s First p53-Modulating Oral Cancer Drug

12/15/2016 12:03 pm

[GlobeNewswire] - BEVERLY, Mass., Dec. 15, 2016-- Cellceutix Corporation,, a clinical stage biopharmaceutical company developing innovative therapies with dermatology, oncology, anti-inflammatory, and antibiotic applications, ...